MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jth.15637

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2022

Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.

Kühne Lucas, Kaufeld Jessica, Völker Linus A, Wendt Ralph, Schönermarck Ulf, Hägele Holger, Osterholt Thomas, Eichenauer Dennis A, Bieringer Markus, von Bergwelt-Baildon Anke, Fischereder Michael, Buxhofer-Ausch Veronika, Menne Jan, Brinkkoetter Paul T, Knöbl Paul

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The anti-von Willebrand factor (VWF) nanobody caplacizumab directly prevents the fatal microthrombi formation in immune-mediated thrombotic thrombocytopenic purpura (iTTP), thereby adding a new therapeutic principle to the treatment of this disorder. However, real-world treatment modalities beyond clinical trials remain heterogeneous.

METHODS

Here, we describe the risks and benefits of an alternate-day dosing regimen for caplacizumab by thoroughly analyzing the timing and outcome of this approach in a retrospective cohort of 25 iTTP patients treated with caplacizumab at seven different medical centers in Austria and Germany between 2018 and 2021.

RESULTS

Alternate-day dosing of caplacizumab appeared feasible and led to persisting normal platelet counts in most patients. Five patients experienced iTTP exacerbations or relapses that led to the resumption of daily caplacizumab application. VWF activity was repeatedly measured in 16 of 25 patients and documented sufficient suppression by caplacizumab after 24 and 48 h in line with published pharmacodynamics.

CONCLUSION

Extension of caplacizumab application intervals from daily to alternate-day dosing may be safely considered in selected patients after 3 to 4 weeks of daily treatment. Earlier modifications may be discussed in low-risk patients but require close monitoring for clinical and laboratory features of thrombotic microangiopathy.

Для цитирования: Kühne Lucas, Kaufeld Jessica, Völker Linus A, Wendt Ralph, Schönermarck Ulf, Hägele Holger, Osterholt Thomas, Eichenauer Dennis A, Bieringer Markus, von Bergwelt-Baildon Anke, Fischereder Michael, Buxhofer-Ausch Veronika, Menne Jan, Brinkkoetter Paul T, Knöbl Paul. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.. Journal of thrombosis and haemostasis : JTH. 2022. DOI: 10.1111/jth.15637.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.